Laurie Barclay, MD NEW YORK (MedscapeWire) May 14
Although statins have been linked to increased risk of myopathy, an article in the May 14 issue of Neurology suggests that peripheral neuropathy may also be a delayed adverse effect. “The positive benefits of statins, particularly on reducing the risk of heart disease, far outweigh the potential risk of developing neuropathy,” lead author David Gaist, MD, PhD, of the University of Southern Denmark in Odense, says in a news release. In this population-based study, the researchers used a patient registry to identify all first cases of idiopathic peripheral neuropathy in Funen County, Denmark, over a 5-year period. Each case was matched to 25 controls of the same age and sex.
Of 166 cases of first-time idiopathic neuropathy, 35 were classified as definite, 54 as probable and 77 as possible cases. Nine of those diagnosed with neuropathy had taken statins, with an average use duration of 2.8 years. Compared with controls, the statin users had a 14.2-fold risk of developing neuropathy classified as definite, and a 3.7-fold risk of developing neuropathy of any classification.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!